PS
EWTX icon

Principal Securities’s Edgewise Therapeutics EWTX Stock Holding History

Principal Securities’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27
Closed -$438 – 2032
2025
Q3 		$438 Hold
27
– – ﹤0.01% 3557
2025
Q2 		$354 Hold
27
– – ﹤0.01% 3535
2025
Q1 		$721 Hold
27
– – ﹤0.01% 3284
2024
Q4 		$721 Hold
27
– – ﹤0.01% 3277
2024
Q3 		$721 Buy
+27
New +$537 ﹤0.01% 3209

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Principal Securities's EWTX Position: Q4 2025 in Review

Principal Securities sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 27 shares — an estimated $438 sold.

Principal Securities first reported a position in EWTX in Q3 2024 and held it in 5 quarters. The position peaked at $721 in Q1 2025. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • Principal Securities reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 27 Edgewise Therapeutics shares in Q4 2025, an estimated $438.
  • Principal Securities first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 5 quarters.
  • Principal Securities's Edgewise Therapeutics position peaked at $721 in Q1 2025.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.